KRAS and non-small cell lung carcinoma: NSCLC patients in the KRAS G12/G13-mutant cfDNA group had significantly (p < 0.001) shorter PFS intervals compared to patients in the KRAS G12/G13-wild type cfDNA group (Figure 1).